Dizal Pharma Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
1,009
- Stock Symbol
-
688192
- Share Price
-
$9.61
- (As of Friday Closing)
Dizal Pharma General Information
Description
Dizal Pharmaceutical Co Ltd, formerly Dizal (Jiangsu) Pharmaceutical Co Ltd is engaged in the research and development, production and sales of innovative drugs.
Contact Information
Website
www.dizalpharma.comCorporate Office
- Jinghui East Road
- Room 4105, Building E (Building 5), Huirong Business Plaza, Xinwu District
- Wuxi City, Jiangsu 201203
- China
Corporate Office
- Jinghui East Road
- Room 4105, Building E (Building 5), Huirong Business Plaza, Xinwu District
- Wuxi City, Jiangsu 201203
- China
Dizal Pharma Stock Performance
As of 13-Nov-2026, Dizal Pharma’s stock price is $9.61. Its current market cap is $4.47B with 465M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $9.61 | $9.76 | $5.28 - $10.31 | $4.47B | 465M | 6.37M | $1.08 |
Dizal Pharma Financials Summary
As of 30-Sep-2026, Dizal Pharma has a trailing 12-month revenue of $723M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,968,325 | 3,673,668 | 2,386,862 | 2,657,307 |
| Revenue | 723,143 | 111,403 | 50,157 | 12,903 |
| EBITDA | 505,155 | (93,075) | (118,846) | (146,730) |
| Net Income | 501,208 | (106,246) | (117,896) | (156,570) |
| Total Assets | 992,087 | 429,135 | 235,440 | 211,096 |
| Total Debt | 192,506 | 177,334 | 158,544 | 57,892 |
Dizal Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Dizal Pharma Comparisons
Industry
Financing
Details
Dizal Pharma Competitors (1)
One of Dizal Pharma’s competitors is Shanghai Henlius, a Formerly VC-backed company based in Shanghai, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Shanghai Henlius | Formerly VC-backed | Shanghai, China |
Dizal Pharma Patents
Dizal Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024255634-A1 | Pharmaceutical forms of quinazoline erbb inhibitors | Pending | 14-Apr-2023 | ||
| EP-4695249-A1 | Pharmaceutical forms of quinazoline erbb inhibitors | Pending | 14-Apr-2023 | ||
| WO-2024213045-A1 | Pharmaceutical forms of quinazoline erbb inhibitors | Inactive | 14-Apr-2023 | ||
| AU-2023335416-A1 | Egfr inhibitors and uses thereof | Pending | 02-Sep-2022 | ||
| EP-4581036-A1 | Egfr inhibitors and uses thereof | Pending | 02-Sep-2022 | C07D498/22 |
Dizal Pharma Signals
Dizal Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Dizal Pharma ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Dizal Pharma FAQs
-
When was Dizal Pharma founded?
Dizal Pharma was founded in 2017.
-
Where is Dizal Pharma headquartered?
Dizal Pharma is headquartered in Wuxi City, China.
-
What is the size of Dizal Pharma?
Dizal Pharma has 1,009 total employees.
-
What industry is Dizal Pharma in?
Dizal Pharma’s primary industry is Drug Discovery.
-
Is Dizal Pharma a private or public company?
Dizal Pharma is a Public company.
-
What is Dizal Pharma’s stock symbol?
The ticker symbol for Dizal Pharma is 688192.
-
What is the current stock price of Dizal Pharma?
As of 13-Nov-2026 the stock price of Dizal Pharma is $9.61.
-
What is the current market cap of Dizal Pharma?
The current market capitalization of Dizal Pharma is $4.47B.
-
What is Dizal Pharma’s current revenue?
The trailing twelve month revenue for Dizal Pharma is $723M.
-
Who are Dizal Pharma’s competitors?
Shanghai Henlius is a competitor of Dizal Pharma.
-
What is Dizal Pharma’s annual earnings per share (EPS)?
Dizal Pharma’s EPS for 12 months was $1.08.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process